SCHEMBL5484482

SCHEMBL5484482

CCOc1cc2c(cc1OC)C(c1ccc(C(=O)N(C(C)C)C(C)C)cc1)=N[C@@H]1CC[C@@H](O)C[C@H]21

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 3/20 0.74
PDE4A P27815 2/20 0.74
PDE4B Q07343 1/20 0.74
PDE4C Q08493 1/20 0.74
LTB4R Q15722 3/20 0.35
SRD5A2 P31213 3/20 0.33
LTB4R2 Q9NPC1 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
CHRM1 P11229 1/20 0.32
PDE3A Q14432 1/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
FPR2 P25090 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473004 0.91 PDE4D (0.62) PDE4DPDE4APDE4BPDE4CLTB4R
SCHEMBL6386266 0.88 PDE4D (0.57) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL1824084 0.86 PDE4D (0.73) PDE4DPDE4APDE4BPDE4CLTB4R
SCHEMBL4187551 0.86 PDE4D (0.73) PDE4DPDE4APDE4BPDE4CLTB4R
SCHEMBL8317685 0.86 PDE4D (0.73) PDE4DPDE4APDE4BPDE4CLTB4R
Pumafentrine SCHEMBL447418 0.85 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CLTB4R
Pumafentrine SCHEMBL26718 0.85 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CLTB4R
SCHEMBL4187035 0.85 PDE4D (0.75) PDE4DPDE4APDE4BPDE4CLTB4R
Pumafentrine SCHEMBL29651667 0.85 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CLTB4R
SCHEMBL7204721 0.85 PDE4D (1.00) PDE4DPDE4APDE4BPDE4CLTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US claimed
EP-1725534-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087745-A1 NOVEL AMIDO-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors ALTANA PHARMA AG (DE) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185149-A1 Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors PDE4A, PDE4B, PDE4C PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.